We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

Germany's Merck KGaA shares plunged after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange headwinds. In European morning trading shares were ...

Roche warned that President Trump's executive order on drug pricing threatens its planned $50 billion investment in the ...

Recursion Pharmaceuticals faces a 57% stock drop amid drug setbacks, rising cash burn, and AI discovery doubts. Learn more ...

CEO Kevin Ali emphasized that recent restructuring efforts and targeted investments in core brands were central to ... Walsh ...

The global CRISPR Market, valued at US$2.90 billion in 2024, is forecasted to grow at a robust CAGR of 11.2%, reaching US$3.21 billion in 2025 and an impressive US$5.47 billion by 2030. The growing ...

The global veterinary antibiotics market is on a strong growth trajectory, anticipated to reach approximately USD 12,820.4 million by 2025 and further expand to an impressive USD 22,559.7 million by ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

Sanofi plans to invest $20 billion in U.S.-based drug R&D and manufacturing over five years, creating jobs and boosting ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

This cash-strapped company is shifting from its roots in cancer drug development to focus on cosmetic treatments.

Leading life science executives, government officials, academic leaders, and investors gather for two day off-the-record ...